Träfflista för sökning "WFRF:(Hubert Ayala) ;pers:(Loman Niklas)"

Sort/group result

Sort by: Hits per page:

Enumeration	Reference	Cover	Find
1.	Domchek, Susan M, et al. (author) Efficacy and safety of olaparib monotherapy in germline BRCA1/2 mutation carriers with advanced ovarian cancer and three or more lines of prior therapy. 2016 In: Gynecologic Oncology. - : Elsevier BV. - 1095-6859 .- 0090-8258. ; 140:2, s. 199-203 Journal article (peer-reviewed)abstract The efficacy and safety of olaparib, an oral poly(ADP-ribose) polymerase (PARP) inhibitor, was investigated in a subgroup of patients with germline BRCA1/2 mutated (gBRCA1/2m) advanced ovarian cancer who had received ≥3 prior lines of chemotherapy. Primary data from this Phase II study (Study 42, ClinicalTrials.govNCT01078662) have been reported previously.
2.	Kaufman, Bella, et al. (author) Olaparib Monotherapy in Patients With Advanced Cancer and a Germline BRCA1/2 Mutation. 2015 In: Journal of Clinical Oncology. - 1527-7755. ; 33:3, s. 134-244 Journal article (peer-reviewed)abstract Olaparib is an oral poly (ADP-ribose) polymerase inhibitor with activity in germline BRCA1 and BRCA2 (BRCA1/2) -associated breast and ovarian cancers. We evaluated the efficacy and safety of olaparib in a spectrum of BRCA1/2-associated cancers.

Skapa referenser, mejla, bekava och länka

Author/Editor: Schmutzler, Rita K. (2); Loman, Niklas (2)Undo refine; Domchek, Susan M. (2); Kaufman, Bella (2); Audeh, M. William (2); Friedlander, Michael (2); show more...; Stemmer, Salomon M. (2); Mitchell, Gillian (2); Balmana, Judith (2); Shapira-Frommer, Ron ... (2); Fried, Georgeta (2); Hubert, Ayala (2); Rosengarten, Ora (2); Aghajanian, Carol (1); Robertson, Jane D (1); Mann, Helen (1); Steiner, Mariana (1); Bowen, Karin (1); Fielding, Anitra (1); show less...

Year

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

Copy and save the link in order to return to this view